ANIP Q2 2018 Earnings — ANI Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ANIPANI Pharmaceuticals, Inc.

$2B

Q2 2018 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$47M+5.6% YoY

Gross Profit

$31M64.9% margin

Operating Income

$7M15.4% margin

Net Income

$3M5.8% margin

EPS (Diluted)

$0.23

QoQ Revenue Growth

+1.7%

Cash Flow

Operating Cash Flow

$9M

Free Cash Flow

$2M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$424M

Total Liabilities

$239M

Stockholders' Equity

$185M

Cash & Equivalents

$55M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$47M	$45M	+5.6%
Gross Profit	$31M	$24M	+29.7%
Operating Income	$7M	$7M	+3.8%
Net Income	$3M	$3M	+3.3%

Revenue Segments

Sales of generic pharmaceutical products

$30M63%

Sales of branded pharmaceutical products

$11M22%

Royalties From Licensing Agreements

$5M10%

Sales of contract manufactured products

$3M5%

Other revenues

$88,0000%